Streptolysin-O reversible permeabilisation is an effective method to transfect siRNAs into myeloma cells

被引:17
作者
Brito, Jose L. R. [1 ]
Davies, Faith E. [1 ]
Gonzalez, David [1 ]
Morgan, Gareth J. [1 ]
机构
[1] Inst Canc Res, Sect Hematooncol, Sutton SM2 5NG, Surrey, England
关键词
multiple myeloma; streptolysin-O; siRNA; transfection;
D O I
10.1016/j.jim.2008.01.009
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
RNA interference (RNAi) has been shown to be a valuable tool to specifically target gene expression in a number of organisms becoming an indispensable weapon in the arsenal in functional genomics. In this study, we demonstrate that streptolysin-O (SLO) reversible permeabilisation is an efficient method to deliver small interfering RNAs (siRNAs) to hard-to-transfect human myeloma cell lines. We used published, pre-validated siRNAs for ERK2 and non-silencing siRNA control. We transfected siRNAs into human myeloma cell lines using SLO reversible permeabilisation method. Flow cytometry and western blot analysis were performed to assess the effect of SLO on transfection efficiency and ERK2 knockdown. These experiments demonstrate that SLO reversible permeabilisation method is an efficient and easy-to-use method to deliver siRNAs into human myeloma cell lines. Optimised SLO permeabilisation method showed to transfect >80% of JIM-3, H929, RPM18226 and U266 cells, with minimal effect on cell viability (< 10%) and cell cycle. Equally important, SLO permeabilisation induced a substantial knockdown of ERK2 at the protein level. These studies demonstrate that reversible SLO permeabilisation can successfully be applied to hard-to-transfect human myeloma cell lines to effectively silence genes. (C) 2008 Published by Elsevier B.V.
引用
收藏
页码:147 / 155
页数:9
相关论文
共 16 条
[1]   Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia [J].
Clark, RE ;
Grzybowski, J ;
Broughton, CM ;
Pender, NT ;
Spiller, DG ;
Brammer, CG ;
Giles, RV ;
Tidd, DM .
BONE MARROW TRANSPLANTATION, 1999, 23 (12) :1303-1308
[2]   The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype [J].
Croonquist, PA ;
Van Ness, B .
ONCOGENE, 2005, 24 (41) :6269-6280
[3]   EFFECT OF STREPTOLYSIN O ON ERYTHROCYTE-MEMBRANES, LIPOSOMES, AND LIPID DISPERSIONS - PROTEIN CHOLESTEROL INTERACTION [J].
DUNCAN, JL ;
SCHLEGEL, R .
JOURNAL OF CELL BIOLOGY, 1975, 67 (01) :160-173
[4]   RNA-triggered gene silencing [J].
Fire, A .
TRENDS IN GENETICS, 1999, 15 (09) :358-363
[5]   SINGLE-BASE DISCRIMINATION FOR RIBONUCLEASE H-DEPENDENT ANTISENSE EFFECTS WITHIN INTACT HUMAN LEUKEMIA-CELLS [J].
GILES, RV ;
RUDDELL, CJ ;
SPILLER, DG ;
GREEN, JA ;
TIDD, DM .
NUCLEIC ACIDS RESEARCH, 1995, 23 (06) :954-961
[6]   Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells [J].
Giles, RV ;
Spiller, DG ;
Grzybowski, J ;
Clark, RE ;
Tidd, DM .
NUCLEIC ACIDS RESEARCH, 1998, 26 (07) :1567-1575
[7]   Mechanism of apoptosis induced by IFN-α in human myeloma cells:: Role of Jak1 and Bim and potentiation by rapamycin [J].
Gomez-Benito, Maria ;
Balsas, Patricia ;
Carvajal-Vergara, Xonia ;
Pandiella, Atanasio ;
Anel, Alberto ;
Marzo, Isabel ;
Naval, Javier .
CELLULAR SIGNALLING, 2007, 19 (04) :844-854
[8]  
Guo Cha, 2006, Zhonghua Xue Ye Xue Za Zhi, V27, P666
[9]   Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro [J].
Haughton, Emma L. ;
Tucker, Steven J. ;
Marek, Carylyn J. ;
Durward, Elaine ;
Leel, Val ;
Bascal, Zainab ;
Monaghan, Tanya ;
Koruth, Matthew ;
Collie-Duguid, Elaina ;
Mann, Derek A. ;
Trim, Julie E. ;
Wright, Matthew C. .
GASTROENTEROLOGY, 2006, 131 (01) :194-209
[10]   Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma [J].
Hurt, EM ;
Wiestner, A ;
Rosenwald, A ;
Shaffer, AL ;
Campo, E ;
Grogan, T ;
Bergsagel, PL ;
Kuehl, WM ;
Staudt, LM .
CANCER CELL, 2004, 5 (02) :191-199